Transfer learning‐trained convolutional neural networks identify novel MRI biomarkers of Alzheimer's disease progression

Abstract

Abstract Introduction Genome‐wide association studies (GWAS) for late onset Alzheimer's disease (AD) may miss genetic variants relevant for delineating disease stages when using clinically defined case/control as a phenotype due to its loose definition and heterogeneity. Methods We use a transfer learning technique to train three‐dimensional convolutional neural network (CNN) models based on structural magnetic resonance imaging (MRI) from the screening stage in the Alzheimer's Disease Neuroimaging Initiative consortium to derive image features that reflect AD progression. Results CNN‐derived image phenotypes are significantly associated with fasting metabolites related to early lipid metabolic changes as well as insulin resistance and with genetic variants mapped to candidate genes enriched for amyloid beta degradation, tau phosphorylation, calcium ion binding‐dependent synaptic loss, APP‐regulated inflammation response, and insulin resistance. Discussion This is the first attempt to show that non‐invasive MRI biomarkers are linked to AD progression characteristics, reinforcing their use in early AD diagnosis and monitoring.

Keywords

• Alzheimer's disease
• convolutional neural networks
• deep learning
• disease progression
• imaging phenotypes
• machine learning